Mythic Therapeutics Launches With New Approach To Improving Antibody Drug Conjugate Performance, Backed By $103 Million In Series B Financing

Mythic Therapeutics today announced its launch to develop smarter and safer antibody-drug conjugates (ADCs) with an oversubscribed Series B financing round of $103 million. Viking Global Investors led the round, along with new investors including Venrock Healthcare Capital Partners, Foresite Capital, Perceptive Advisors, and Highside Capital. Existing Mythic investors participating in the round include Venrock, First Round Capital, OMX Ventures, Lifeforce Capital, and Refactor Capital. The proceeds from Mythic’s Series B will finance the lead program through first-in-human clinical studies in lung cancer and fund pipeline development.